Univ.-Prof. Dr. Andreas Koeberle
+43 316 380 - 8630
Institute for Pharmaceutical Sciences
University of Graz
Beethovenstraße 8
Room: 111-01-0088
ORCID: 0000-0001-6269-5088
Andreas is a full professor and head of the Pharmacognosy section at the University of Graz. He holds a degree in biochemistry and earned his Ph.D. in Medicinal Chemistry/Analytics from the University of Tuebingen, Germany, in 2009. Following postdoctoral research at the University of Tokyo, Japan, he joined the University of Jena as junior group leader and established the institutional lipidomics facility within the Chair of Medicinal/Pharmaceutical Chemistry. In 2018, he was appointed visiting professor at the University of Vienna, and, in 2019, he accepted a full professorship for New Phyto Entities at the University of Innsbruck, where he established and led the Michael Popp Institute until 2024. His research has been funded by the Austrian Science Fund (FWF), German Research Foundation (DFG), Phospholipid Research Center (PRC), Michael A. Popp Nature Science Foundation, and industrial collaborations and has been honored by several national and international awards. Currently, he focuses on the mechanistic links between lipid metabolism and lipid signaling at the crossroads of inflammation, cancer, and cellular homeostasis, with special emphasis on identifying innovative drug targets and biogenic lead compounds in programmed cell death (ferroptosis) and the resolution of inflammation.
Funding
2023-2027: FWF(P 36299) "Lipid metabolic mechanisms of EMT/ZEB1-dependent ferroptosis"
2023-2026: BMBWF (Digital Research Infrastructure) DigiOmics4Austria (co-applicant/collaborator)
2023-2024: Member of theCOST Action CA19105 Pan-European Network in Lipidomics and EpiLipidomics (EpiLipidNET)
2022-2023: Phospholipid Research Centre (PRC) "Potential of phosphatidylcholines with ω3 fatty acids in antileukemic combination therapy"
2020-2023: FWF (I 4968) "Dual inhibitors inspired from vitamin E"
2020-2024: Bionorica Research "Characterisation of natural products, plant extracts and phytopharmaceuticals using molecular biological techniques"
2019-2024: University of Innsbruck/Michael A. Popp Nature Science Foundation: Construction of the Unit New Phyto Entities at the newly founded Michael Popp Research Institute
2019-2022: Phospholipid Research Center Heidelberg (PLRC) "Potential of algal phosphatidylcholines containing ω3 fatty acids in the supportive therapy of leukemia and lymphoma"
2018-2021: GRK 1715 (DFG) "Molecular signatures of adaptive stress reactions"; joint project with the Nutritional Science, Univ. Jena: "Endogenous metabolites of α-tocopherol as double-edged swords in the regulation of inflammatory stress"
2018-2019: DAAD, exchange program (57389523) "Dual inhibitors of 5-LO and mPGES-1 based on vitamin E analogs (DIVA)"
2018-2021: Joint PhD Programme of the Universities Shenzhen and Jena; joint project with the School of Medicine, Univ. Shenzen "Novel mechanism(s) governing CD36 protein degradation and metabolic homeostasis"
2018-2021: GRK 1715 (DFG) Support for lipidomics-based projects (associated PI)
2017-2020: DFG(KO 4589/7-1) "5-Lipoxygenase as immunoregulatory target of human endogenous vitamin E metabolites"
2017-2019: Free State of Thuringia - Start-up project of the excellence cluster "Balance of the Microverse"; joint project with partners from the Univ. Hospital Jena and Univ. Jena: "Role of lipid transfer from host cells to S. aureus during chronic infection and consequences for host immune response"
2017-2018: Phospholipid Research Centre Heidelberg (PLRC) "Combination of phosphatidylcholine-bound polyunsaturated fatty acids with cytoskeleton-targeting drugs for overcoming Akt-dependent chemoresistance"
2015-2018: GRK 1715 (DFG) "Molecular signatures of adaptive stress reactions"; Project: "Overcoming persistence mechanisms of anti-tumoral agents by modulating the membrane phospholipid composition" (associated PI)
2015-2017: Univ. Jena, funding programme "advanced": "Metabolites of vitamin E as nanomolar inhibitors of 5-lipoxygenase"
2014-2015: Bionorica Global Research Initiative 2013/2014 "Targeting of bioactive lipid networks: a novel pharmacological strategy for anti-inflammatory phytomedicine"
2014-2016: DFG(KO 4589/4-1) "Role of stearoyl-CoA desaturase-1 for the regulation of ER homeostasis by stearoyl-CoA desaturase-1"
2014-2017: Phospholipid Research Centre Heidelberg (PLRC) "Inhibition of Akt by polyunsaturated phosphatidylcholine - a novel approach for anti-cancer therapy"
2013-2014: Univ. Jena, funding programme "basic": "Lipids as potential modulators of cancer initiation and progression"
Awards and honors
2024: Offer to lead the section Pharmacognosy, Institute of Pharmaceutical Sciences, University Graz
2019-2024: Endowed professorship as head of a newly established institute (Michael A. Popp Nature Science Foundation/University of Innsbruck)
2019: EFMC Prize for a Young Medicinal Chemist in Academia" (EFMC)
2018: Guest professor at the University of Vienna (Pharmacognosy)
2018: Habilitation award of the Friedrich-Schiller-University Jena
2017: Offer of the chair of Pharm./Med. Chemistry, PMU, Salzburg
2017: Runner-up of the "EFMC Prize for a Young Medicinal Chemist in Academia" (EFMC)
2016: Innovation Award in Medicinal/Pharmaceutical Chemistry (GDCh/DPhG)
2014: First place award of the "Young Scientist Symposium" of the "5th European Workshop on Lipid Mediators" (ESLM)
2009: Klaus-Grohe-Award for Medicinal Chemistry (German Chemical Society GDCh)
2009-2011: Post-Doc fellowship of Takeda Science Foundation, DPhG and PSJ (Japan)
2006: Participation at the "18th meeting of nobel laureates in Chemistry in Lindau"
2000: Award of the German Chemical Industry as best graduate in Chemistry (HZG, Sigmaringen, Germany)